Literature DB >> 31407551

[Short-term effectiveness of unicompartmental knee arthroplasty for knee osteoarthritis in super-age patients].

Fangxing Wang1, Huaming Xue1, Tong Ma1, Tao Wen1, Tao Yang1, Long Xue1, Yihui Tu2.   

Abstract

OBJECTIVE: To investigate the short-term effectiveness of unicompartmental knee arthroplasty (UKA) in the treatment of knee osteoarthritis of super-age patients over 85 years old.
METHODS: Senile patients with unilateral compartment osteoarthritis of the knee who received UKA between November 2013 and May 2017 and met the inclusion criteria were enrolled as the research objects. Among them, 40 patients (50 knees) were more than 85 years old (super-age group) and 44 patients (50 knees) were 52-81 years old (control group). There was significant difference in age between the two groups ( t=17.33, P=0.00). There was no significant difference in body mass index, degenerative classification of medial and lateral compartments, varus deformity of knee, disease duration, complicating diseases, and preoperative hemoglobin, hematocrit (HCT), American Hospital for Special Surgery (HSS) score, range of motion (ROM) of knee, visual analogue scale (VAS) score, and femoral-tibial angle (FTA) between the two groups ( P>0.05). Hospital stay, hemoglobin, and HCT of the two groups were recorded before operation and on the first day after operation. The changes of hemoglobin and HCT after operation were calculated. During follow-up period, the ROM of the knee, HSS score, and VAS score were measured; the position of the prosthesis and FTA were observed by X-ray films.
RESULTS: There was no significant difference in hospital stay between the two groups ( t=1.05, P=0.29). Hemoglobin and HCT of the two groups on the first day after operation were significantly lower than those before operation ( P<0.05). There was no significant difference in the postoperative changes of hemoglobin and HCT between the two groups ( P>0.05). All the patients were followed up completely except 4 cases (5 knees) in the super-age group. The follow-up time ranged from 14 to 44 months of super-age group (mean, 29 months) and 21 to 33 months of control group (mean, 24 months). There were significant differences in HSS score, VAS score, ROM of the knee, and FTA between pre-operation and last follow-up in the two groups ( P<0.05). There was significant difference in HSS score between the two groups ( P<0.05), and no significant difference was found in ROM, VAS score, and FTA between the two groups ( P>0.05). X-ray film showed no adverse position of the prosthesis, infection around the prosthesis, prosthesis loosening, or pathological bright lines.
CONCLUSION: UKA combined with reasonable perioperative management in the treatment of super-age patients over 85 years with knee osteoarthritis is safe and feasible, and can obtain satisfactory short-term effectiveness.

Entities:  

Keywords:  Unicompartmental knee arthroplasty; knee; osteoarthritis; super-age patient

Mesh:

Year:  2019        PMID: 31407551      PMCID: PMC8337903          DOI: 10.7507/1002-1892.201811061

Source DB:  PubMed          Journal:  Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi        ISSN: 1002-1892


  17 in total

1.  Predictors of rehospitalization for symptomatic venous thromboembolism after total hip arthroplasty.

Authors:  R H White; S Gettner; J M Newman; K B Trauner; P S Romano
Journal:  N Engl J Med       Date:  2000-12-14       Impact factor: 91.245

2.  [Detection of asymptomatic venous thrombosis after lower limb prosthetic surgery. Retrospective evaluation of a systematic approach using Doppler ultrasonography: 400 cases].

Authors:  E de Thomasson; C Strauss; P Girard; I Caux; O Guingand; C Mazel
Journal:  Presse Med       Date:  2000-02-26       Impact factor: 1.228

3.  Impact of osteoarthritis: results of a nationwide survey of 10,000 patients consulting for OA.

Authors:  Bruno Fautrel; Pascal Hilliquin; Sylvie Rozenberg; François-André Allaert; Philippe Coste; Annette Leclerc; Michel Rossignol
Journal:  Joint Bone Spine       Date:  2005-05       Impact factor: 4.929

4.  Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II.

Authors:  Reva C Lawrence; David T Felson; Charles G Helmick; Lesley M Arnold; Hyon Choi; Richard A Deyo; Sherine Gabriel; Rosemarie Hirsch; Marc C Hochberg; Gene G Hunder; Joanne M Jordan; Jeffrey N Katz; Hilal Maradit Kremers; Frederick Wolfe
Journal:  Arthritis Rheum       Date:  2008-01

5.  Preoperative pain location is a poor predictor of outcome after Oxford unicompartmental knee arthroplasty at 1 and 5 years.

Authors:  A D Liddle; H Pandit; C Jenkins; A J Price; C A F Dodd; H S Gill; D W Murray
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2012-09-22       Impact factor: 4.342

6.  Medial unicompartmental knee arthroplasty with the Miller-Galante prosthesis.

Authors:  Douglas Naudie; Jeff Guerin; David A Parker; Robert B Bourne; Cecil H Rorabeck
Journal:  J Bone Joint Surg Am       Date:  2004-09       Impact factor: 5.284

7.  Unicondylar knee arthroplasty. An evaluation of selection criteria.

Authors:  S H Stern; M W Becker; J N Insall
Journal:  Clin Orthop Relat Res       Date:  1993-01       Impact factor: 4.176

8.  Pre-operative clinical and radiological assessment of the patellofemoral joint in unicompartmental knee replacement and its influence on outcome.

Authors:  D J Beard; H Pandit; S Ostlere; C Jenkins; C A F Dodd; D W Murray
Journal:  J Bone Joint Surg Br       Date:  2007-12

9.  Determinants of revision and functional outcome following unicompartmental knee replacement.

Authors:  A D Liddle; A Judge; H Pandit; D W Murray
Journal:  Osteoarthritis Cartilage       Date:  2014-07-17       Impact factor: 6.576

10.  The learning curve for minimally invasive Oxford phase 3 unicompartmental knee arthroplasty: cumulative summation test for learning curve (LC-CUSUM).

Authors:  Qidong Zhang; Qian Zhang; Wanshou Guo; Zhaohui Liu; Liming Cheng; Debo Yue; Nianfei Zhang
Journal:  J Orthop Surg Res       Date:  2014-09-06       Impact factor: 2.359

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.